



PelliScope

AI-Powered Dermatological Decision Support



HawkFranklin
Research

01 | THE PRODUCT

Clinically-Validated AI For Any Workflow

READY TO DEPLOY FOR



Pre-Medical Inquiry

Triage before the patient sees a doctor



Tele-Medicine Consultation

Cost-effective remote patient consultation



In-Patient Appointment Schedule

Prioritize urgency while sharing interim home care guidance

Patient Scan: #8829-A

ANALYSIS COMPLETE



PRIMARY DETECTION

Herpes Zoster

74%

Confidence

Allergic Dermatitis

59%

▶ Application Demo (PC)

📱 Mobile Demo

🛡️ 80.2% Accuracy on Clinical Validation

Core Capabilities



Instant Clinical Support

Instantly distinguishes between **infectious vs. non-infectious** lesions to protect staff.



Diagnostic Assessment

Probability scoring for **10 common conditions** (Eczema, Psoriasis, Tinea, etc.).



CPU-Optimized



Resource optimized for any hardware. On-premises deployable—data never leaves your control.

< Prev

Next >

02 | PRE-CONSULTATION EFFICIENCY

UNIT ECONOMICS (DAILY)





Deployment Readiness

Federal Partnership & Regional Rollout



HawkFranklin
Research

03 | STRATEGIC IMPLEMENTATION

STATUS: ACTIVE ENGAGEMENT

Dubai, UAE

Federal Healthcare Integration

We are in advanced discussions with the **Emirates Health Services (EHS)** to integrate PelliScope into the federal clinical pipeline. The solution is shortlisted for a PoC to validate efficacy across EHS facilities.

✓ Shortlisted for PoC

Microphone icon Invited to WHX & Arab Health 2026

PDF icon DOCUMENT

Official Letter of Acknowledgement

From Emirates Health Services

Chart icon Market Relevance

\$1.9 Billion

2024 Global Valuation

The scale of the market validates the necessity for automated triage. High demand in GCC & US hospital systems.

Upward arrow icon Adoption Velocity

33% CAGR

Projected 2025–2035

Demand driven by tele-dermatology adoption and the need for onsite non-specialist triage.

Map icon Deployment Roadmap

- Proof of Concept (Current)
Shortlisted by EHS Evaluation Committee
- WHX & Arab Health 2026
Official Tech Showcase at EHS Booth
- Full Integration
Clinical Pipeline Deployment

< Prev

Next >



The Engine


Architecture & Methodology



04 | SOLUTION ARCHITECTURE

Multiple Instance Learning

Frozen Embeddings



Why Multiple Instance Learning?

Standard AI analyzes single images in isolation, missing the full picture. **PelliScope** mimics a dermatologist by aggregating evidence from multiple views (close-up details + body context) before making a decision.

Benchmark Performance

Zero-shot comparison (Micro ROC-AUC)

0.86

Top Tier



TRAINING & VALIDATION RESOURCES

Curated Proprietary Dataset

Multi-view patient cases with rigorous 60/20/20 split to prevent data leakage.

Privacy-First Architecture

Original patient images are processed once. Only mathematical embeddings (non-reconstructible) are stored.

Inference Speed: ~6 sec / case on Standard CPU

< Prev

Next >



Investment Opportunity

Scaling for the Indian and Southeast Asian Markets



HawkFranklin
Research

05 | FUNDING REQUIREMENTS

HawkFranklin Research is entirely **bootstrapped** and driven by internal funds. We have strong technical validation and an active engagement in the GCC (UAE). We seek strategic capital to scale PelliScope specifically across India and Southeast Asia (SEA), which are distinct target markets.

PHASE 1: INDIA (1 Year)

₹ Local Deployment & Data

₹50 Lakhs

(Approx. \$60,000 USD)

- ✓ Field Data Collection & Dermatologist feedback loop.
- ✓ Deployment of scalable services for hospitals and clinics.
- ✓ Regulatory compliance preparation for Indian market.

PHASE 2: SOUTHEAST ASIA EXPANSION

🌐 Regional Scale & Market Entry

\$1.0 Million

(USD)

- ✓ Establish regional presence and secure partnerships.
- ✓ Target markets: **Singapore, Vietnam, Indonesia, Philippines**.
- ✓ Regulatory adaptation and launch campaigns across SEA.

Partner with Us



Email Our Team

invest@hawkfranklin.in

HawkFranklin Research is a deep-tech company specializing in clinical AI solutions, driven by science and commercial rigor.

TOTAL MARKET VALUE

\$1.9 Billion

2024 Global AI Dermatology

WIDER PORTFOLIO SYNERGY

Cancer Genomics
Quantum AI

EARLY INVESTOR POTENTIAL

5x ROI

1 18 20 M Timeline

< Prev

Next >



Leadership

The PelliScope Team



06 | PELLISCOPE TEAM



Vatsal Patel
Founder & Research Engineer
M.Sc Artificial Intelligence (IU Berlin)



Dr. Abhijeet Patel
Clinical Research Physician
Bachelor of Medicine & Surgery



Dr. Yash Patel
Clinical Research Physician
Bachelor of Medicine & Surgery



Dr. Nishi Seth
Consultant Dermatologist
M.D Dermatology



Saurav Roy
Operations Head
M.Tech Biotechnology



Ananya Pal
Finance & Accounting Head
B.S Economics

< Prev

Next >



Vision & Portfolio

How HawkFranklin Operates



HawkFranklin
Research

Operational Revenue Model



Path A: HFR-Initiated Products

We identify a market gap, build a validated product (like PelliScope), and then seek commercial partners to scale it.



Path B: Partner-Initiated R&D

You bring a defined challenge. We build the dedicated AI solution, acting as your external deep-tech R&D team.

Our Philosophy

HawkFranklin's long-term vision is to innovate science with commercial rigor. Our team spans physicists, chemists, biologists, and AI engineers who are building breakthroughs across quantum computing, finance, and healthcare.

"We are a resilient, self-funded team. We will succeed with or without external funding—this is an opportunity to join a team that is already moving forward."

BROADER BIOMEDICAL PORTFOLIO



OncoGemma

AI agents for digital pathology analysis



C-Risq

Multi-omics for cancer risk stratification



MedDiscover

RAG copilot for biomedical Q&A



Clinical FM

Foundation models for tabular EHR data

Beyond PelliScope, we maintain specialist pods across these domains to spin up commercialization-ready products wherever the science demands it.



< Prev

Contact Us